The Dutch medtech giant designed VeriSight Pro 3D to deliver real-time 3D imaging directly inside the heart. It helps physicians perform procedures with greater clarity and without the need for general anesthesia.
VeriSight goes through a patient’s blood vessels until it lies directly inside the chambers of the heart. It aids in planning and guiding complicated interventional procedures by delivering high-quality imaging. The system can help characterize difficult-to-image heart structures like the left atrial appendage or tricuspid valve, for instance, aiding in procedures like transcatheter valve repair and appendage closure.
Philips reported the first use cases in the U.S. in 2021. In 2023, the company had positive data on VeriSight come out of the Mayo Clinic. Last year, Philips announced hospitals in Hong Kong used VeriSight Pro, marking its first uses outside the U.S.
“VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience,” said Stacy Beske, business leader of Image-Guided Therapy Devices at Philips. “Its availability in Europe is an important milestone in helping more patients benefit from image-guided, minimally invasive heart procedures, while supporting care teams with integrated solutions that adapt to the way they work.”
